Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global Select Market under the symbol “HZNP.”

Horizon Pharma plc is a specialty biopharmaceutical company focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. Horizon Pharma’s global headquarters are in Dublin, Ireland.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jeffrey C. Lau, Katherine Schloss Ackerman and Caitlin Moyles Cunnane. Partner Rachel D. Kleinberg provided tax advice. The intellectual property and technology team included partner David R. Bauer and associates Michael V. Policastro and Jay Frankel. Associate J. Taylor Arabian provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post